Adverse drug reactions
Executive Summary
FDA Center for Durgs & Biologics Acting Director Paul Parkman, MD, noted at a Fed. 19 meeting of the Pharmaceutical Advertising Council that the agency received 60,000 adverse drug reaction reports in 1986. The figure is an increase of 62.5% over the 36,931 reports received in 1985 ("The Pink Sheet" Feb. 9, T&G-5).
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.